EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer

Makenna A Smack iD, Jane E Rogers iD, Lianchun Xiao, Sunyoung S Lee, Shubham Pant, Ahmed O Kaseb iD, Brandon G Smaglo, Victoria Higbie, Zishou Ian Hu, Amy An, Milind Javle

Cancers · 11.06.2026 · 18 (12) · 1901

DOI: 10.3390/cancers18121901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 11.06.2026. Verfasst von Makenna A Smack und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marther fund, Mark Mobius fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gemcitabine, cisplatin and durvalumab or pembrolizumab are standard first-line treatments for advanced or metastatic biliary tract cancer (BTC). Older patients with BTC may be frail or have contraindications to cisplatin. At our institution, oxaliplatin has been used as an alternative to cisplatin.

Methods

In this evaluation, we report the safety and efficacy of gemcitabine with oxaliplatin and durvalumab as a first-line treatment of BTC. The primary objective was overall survival (OS). Secondary objectives included time to progression (TTP), disease control rate (DCR), and the incidence of treatment-related toxicities.

Results

Twenty-nine patients were included. The majority were Caucasian (97%) and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 (97%). Median age was 72 years old. Sixty-six percent had intrahepatic cholangiocarcinoma. Baseline renal insufficiency and/or hearing impairment were the most common reasons for cisplatin contraindication. Median follow-up was 20.6 months. Treatment cycles were every 28 days with durvalumab (1500 mg) given on day 1 and gemcitabine (range 600 mg/m2–1000 mg/m2) plus oxaliplatin (median dose 70 mg/m2) given on days 1 and 15. Median OS was 15.7 months (95% CI: 6.9-NA), median TTP was 6.7 months (95% CI 3.88-NA), and DCR was 76%. Median time on treatment was 3.15 months. Twelve patients (41%) required a dose adjustment, with myelosuppression as the most common toxicity.

Conclusions

Oxaliplatin, in combination with durvalumab and gemcitabine, is a suitable platinum substitute for advanced BTC patients when cisplatin is contraindicated. Our analysis showed similar efficacy and no new safety concerns. Given the small sample size, our analysis is hypothesis-generating and calls for a larger prospective analysis.

Schlagwörter

Stichwörter der Autor:innen

biliary cancerbiotherapychemotherapycholangiocarcinomagallbladder cancerplatinum chemotherapy

Autor:innen und Institutionen

  • Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Makenna A Smack, Jane E Rogers, Ahmed O Kaseb

Förderung

  • Marther fund
  • Mark Mobius fund

Zitieren

APA

Smack, M. A., Rogers, J. E., Xiao, L., Lee, S. S., Pant, S., Kaseb, A. O., Smaglo, B. G., Higbie, V., Hu, Z. I., An, A., & Javle, M. (2026). Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer. Cancers, 18(12), 1901. https://doi.org/10.3390/cancers18121901

Vancouver

Smack MA, Rogers JE, Xiao L, Lee SS, Pant S, Kaseb AO, et al. Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer. Cancers. 2026;18(12):1901. doi:10.3390/cancers18121901

BibTeX
@article{Smack2026,
  author = {Smack, Makenna A and Rogers, Jane E and Xiao, Lianchun and Lee, Sunyoung S and Pant, Shubham and Kaseb, Ahmed O and Smaglo, Brandon G and Higbie, Victoria and Hu, Zishou Ian and An, Amy and Javle, Milind},
  title = {Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1901},
  doi = {10.3390/cancers18121901}
}
Kostenlos starten →